227 related articles for article (PubMed ID: 24507810)
1. Myelodysplastic Syndromes (MDS) and autoimmune disorders (AD): cause or consequence?
Braun T; Fenaux P
Best Pract Res Clin Haematol; 2013 Dec; 26(4):327-36. PubMed ID: 24507810
[TBL] [Abstract][Full Text] [Related]
2. [Systemic and autoimmune manifestations in myelodysplastic syndromes].
Fain O; Braun T; Stirnemann J; Fenaux P
Rev Med Interne; 2011 Sep; 32(9):552-9. PubMed ID: 20850913
[TBL] [Abstract][Full Text] [Related]
3. Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes.
Montoro J; Gallur L; Merchán B; Molero A; Roldán E; Martínez-Valle F; Villacampa G; Navarrete M; Ortega M; Castellví J; Saumell S; Bobillo S; Bosch F; Valcárcel D
Ann Hematol; 2018 Aug; 97(8):1349-1356. PubMed ID: 29572561
[TBL] [Abstract][Full Text] [Related]
4. Myelodysplastic syndromes: the role of the immune system in pathogenesis.
Warlick ED; Miller JS
Leuk Lymphoma; 2011 Nov; 52(11):2045-9. PubMed ID: 21663505
[TBL] [Abstract][Full Text] [Related]
5. Kinetics, function and bone marrow trafficking of CD4+CD25+FOXP3+ regulatory T cells in myelodysplastic syndromes (MDS).
Kotsianidis I; Bouchliou I; Nakou E; Spanoudakis E; Margaritis D; Christophoridou AV; Anastasiades A; Tsigalou C; Bourikas G; Karadimitris A; Tsatalas C
Leukemia; 2009 Mar; 23(3):510-8. PubMed ID: 19020538
[TBL] [Abstract][Full Text] [Related]
6. Autoimmune manifestations associated with myelodysplastic syndromes.
Grignano E; Jachiet V; Fenaux P; Ades L; Fain O; Mekinian A
Ann Hematol; 2018 Nov; 97(11):2015-2023. PubMed ID: 30091023
[TBL] [Abstract][Full Text] [Related]
7. Anti-TNF therapy in patients with rheumatoid arthritis decreases Th1 and Th17 cell populations and expands IFN-γ-producing NK cell and regulatory T cell subsets.
Aravena O; Pesce B; Soto L; Orrego N; Sabugo F; Wurmann P; Molina MC; Alfaro J; Cuchacovich M; Aguillón JC; Catalán D
Immunobiology; 2011 Dec; 216(12):1256-63. PubMed ID: 21840621
[TBL] [Abstract][Full Text] [Related]
8. Myelodysplasia-associated autoimmunity: clinical and pathophysiologic concepts.
Voulgarelis M; Giannouli S; Ritis K; Tzioufas AG
Eur J Clin Invest; 2004 Oct; 34(10):690-700. PubMed ID: 15473894
[TBL] [Abstract][Full Text] [Related]
9. Autoimmune phenomena in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Saif MW; Hopkins JL; Gore SD
Leuk Lymphoma; 2002 Nov; 43(11):2083-92. PubMed ID: 12533032
[TBL] [Abstract][Full Text] [Related]
10. Th17 and Foxp3(+) T regulatory cell dynamics and distribution in myelodysplastic syndromes.
Bouchliou I; Miltiades P; Nakou E; Spanoudakis E; Goutzouvelidis A; Vakalopoulou S; Garypidou V; Kotoula V; Bourikas G; Tsatalas C; Kotsianidis I
Clin Immunol; 2011 Jun; 139(3):350-9. PubMed ID: 21444247
[TBL] [Abstract][Full Text] [Related]
11. Activation of cytotoxic T-cell receptor gammadelta T lymphocytes in response to specific stimulation in myelodysplastic syndromes.
Kiladjian JJ; Visentin G; Viey E; Chevret S; Eclache V; Stirnemann J; Bourhis JH; Chouaib S; Fenaux P; Caignard A
Haematologica; 2008 Mar; 93(3):381-9. PubMed ID: 18268282
[TBL] [Abstract][Full Text] [Related]
12. Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy.
Enright H; Jacob HS; Vercellotti G; Howe R; Belzer M; Miller W
Br J Haematol; 1995 Oct; 91(2):403-8. PubMed ID: 8547082
[TBL] [Abstract][Full Text] [Related]
13. [Systemic diseases in myelodysplastic syndromes].
Hebbar M; Hebbar-Savéan K; Fenaux P
Rev Med Interne; 1995; 16(12):897-904. PubMed ID: 8570952
[TBL] [Abstract][Full Text] [Related]
14. CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.
Gleason MK; Ross JA; Warlick ED; Lund TC; Verneris MR; Wiernik A; Spellman S; Haagenson MD; Lenvik AJ; Litzow MR; Epling-Burnette PK; Blazar BR; Weiner LM; Weisdorf DJ; Vallera DA; Miller JS
Blood; 2014 May; 123(19):3016-26. PubMed ID: 24652987
[TBL] [Abstract][Full Text] [Related]
15. Myelodysplasia and autoimmunity.
Giannouli S; Kanellopoulou T; Voulgarelis M
Curr Opin Rheumatol; 2012 Jan; 24(1):97-102. PubMed ID: 22157417
[TBL] [Abstract][Full Text] [Related]
16. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis.
Stifter G; Heiss S; Gastl G; Tzankov A; Stauder R
Eur J Haematol; 2005 Dec; 75(6):485-91. PubMed ID: 16313260
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of flow cytometric assessment of myeloid nuclear differentiation antigen expression as a diagnostic marker for myelodysplastic syndromes in a series of 269 patients.
Bellos F; Alpermann T; Gouberman E; Haferlach C; Schnittger S; Haferlach T; Kern W
Cytometry B Clin Cytom; 2012 Sep; 82(5):295-304. PubMed ID: 22508616
[TBL] [Abstract][Full Text] [Related]
18. Impact of Bone Marrow Natural Killer Cells (NK); Soluble TNF-α and IL-32 Levels in Myelodysplastic Syndrome Patients.
Aref S; Khaled N; Al Gilany AH; Ayed M; Abouzeid T; Attia D
Asian Pac J Cancer Prev; 2020 Oct; 21(10):2949-2953. PubMed ID: 33112553
[TBL] [Abstract][Full Text] [Related]
19. Myelodysplastic syndrome associated with multiple autoimmune disorders.
Farmakis D; Polymeropoulos E; Polonifi A; Deftereos S; Giakoumi X; Floudas H; Grapsa A; Aessopos A
Clin Rheumatol; 2005 Aug; 24(4):428-30. PubMed ID: 15827686
[TBL] [Abstract][Full Text] [Related]
20. [Myelodysplastic syndromes and autoimmunity].
Stalder G; Alberio L; Ribi C
Rev Med Suisse; 2015 Apr; 11(469):820-2, 824-5. PubMed ID: 26040163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
